The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review

Since bevacizumab was first approved by the U.S. Food and Drug Administration as an anti-angiogenic therapy in 2004, angiogenesis-targeted therapy has been developed for various types of solid tumors. To date, ramucirumab and apatinib are clinically available as treatments for metastatic advanced ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Izuma, Takahari, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178968/
https://www.ncbi.nlm.nih.gov/pubmed/37176668
http://dx.doi.org/10.3390/jcm12093226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178968/
https://www.ncbi.nlm.nih.gov/pubmed/37176668
http://dx.doi.org/10.3390/jcm12093226

Ejemplares similares